Curie.Bio is a Boston-based venture capital firm founded in 2022 by Alexis Borisy, Zach Weinberg. See contact routes.
Curie.Bio is a Boston-based venture capital firm founded in 2022 by Alexis Borisy, Zach Weinberg, and Christoph Lengauer to help scientists launch biotech therapeutics companies. The firm operates as a founder-focused seed-stage investor combined with a therapeutics accelerator, investing primarily in early-stage companies developing assets with potential annual sales exceeding $1 billion across modalities like small molecules, antibodies, and gene therapies. Curie.Bio typically provides seed investments ranging from $7 million to $12 million and acts as an operating partner by embedding drug-development teams inside startups to ensure they reach clinical milestones. While the firm has tracked over 26 investments across 23 companies, it has not publicly disclosed specific named portfolio companies or therapeutics programs. The firm raised an initial $520 million fund in early 2023 and secured an additional $380 million in June 2024, bringing its total capital to nearly $1 billion, with a later reported total of $1.2 billion. Curie.Bio distinguishes itself by functioning as a “drug discovery co-pilot,” offering founders access to 50 drug hunte
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Boston.
Investors like Curie.Bio · Full investor directory · Investor access · Company funding database